A Study of Lasmiditan in Participants With Migraine

Status Completed

Clinical Trial Summary

The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.

Information about any side effects that may occur will also be collected.

This study includes two study periods. Each study period requires an overnight stay in the Clinical Research Unit (CRU) for at least one night (and up to three nights), followed by up to two outpatient appointments. This study will last approximately 5-6 weeks (not including screening).

Follow-up is required four to seven days after last dose of investigational drug. Screening is required within 28 days prior to the start of the study.

This study is for research purposes only and is not intended to treat any medical condition.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Migraine Disorders

Clinical Trial Details

NCT number	NCT03247790
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 1
Start date	August 16, 2017
Completion date	January 15, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01432379` - BOTOX® Prophylaxis in Patients With Chronic Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05048914` - Migraine Abortive Treatment
Completed	`NCT03662295` - Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
Completed	`NCT02766517` - Biomarker Study in Participants With Migraine	Early Phase 1
Completed	`NCT00963937` - Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents	Phase 3
Not yet recruiting	`NCT03632928` - Day to Day Variation of Pressure Pain Threshold and Muscle Hardness
Completed	`NCT02559895` - A Multicenter Assessment of ALD403 in Frequent Episodic Migraine	Phase 3
Completed	`NCT01435941` - Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine	N/A
Completed	`NCT00743015` - Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks	Phase 1
Completed	`NCT01376141` - Drug Use Investigation for IMIGRAN Tablet	N/A
Completed	`NCT02183688` - Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients	Phase 3
Completed	`NCT06061588` - "Potential Effects of Virtual Reality Technology on the Treatment of Migraine-Type Headaches"	N/A
Completed	`NCT03588364` - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine	N/A
Completed	`NCT04091321` - Association Between Chronic Headache and Back Pain With Childbirth
Completed	`NCT00385008` - TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine	Phase 3
Active, not recruiting	`NCT05888298` - Proximal and Distal Approach GON RFT in Migraine	N/A
Completed	`NCT03435185` - Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients	N/A
Recruiting	`NCT06459635` - Migraine Attack Pain Phase Prediction Study
Completed	`NCT02565186` - An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine	Phase 3